Table 1.
Comparison between women and men with concomitant rosacea and basal cell carcinoma
| Parameter | Women (n = 31) | Men (n = 20) | P-value |
|---|---|---|---|
| Age [years] mean ± SD (range) | 70.2 ±9.6 (52–87) | 71.6 ±9.7 (50–86) | NS |
| BCC location: | NS | ||
| Cheeks | 11 (35.5%) | 4 (20%) | |
| Nose | 12 (38.7%) | 11 (55%) | |
| Forehead | 5 (16.1%) | 2 (10%) | |
| Eyelids | 2 (6.5%) | 1 (5%) | |
| Lips | 1 (3.2%) | 0 | |
| Temporal area | 0 | 1 (5%) | |
| Other | 0 | 1 (5%) | |
| Clinical type of BCC: | NS | ||
| Nodular | 26 (83.8%) | 18 (90%) | |
| Superficial | 0 | 0 | |
| Pigmented | 0 | 1 (5%) | |
| Morpheaform | 0 | 0 | |
| Ulcerative | 5 (16.1%) | 1 (5%) | |
| Subtype of rosacea: | NS | ||
| Erythematotelangiectatic | 31 (100%) | 19 (95%) | |
| Papulopustular | 0 | 0 | |
| Phymatous | 0 | 0 | |
| Ocular | 0 | 1 (5%) | |
| Rosacea intensity (IGA scale): | NS | ||
| Grade 1 | 20 (64.5%) | 12 (60%) | |
| Grade 2 | 10 (32.3%) | 7 (35%) | |
| Grade 3 | 1 (3.2%) | 1 (5%) | |
| Grade 4 | 0 | 0 |
IGA – Investigator’s Global Assessment, BCC – basal cell carcinoma, SD – standard deviation, NS – not significant.